On Wednesday, Piper Sandler adjusted its outlook on shares of Vicarious Surgical Inc. (NYSE: RBOT), reducing the price target to $10.50 from the previous $12.00 while maintaining a Neutral rating on the stock. The adjustment follows the company's announcement of its third-quarter results, which disclosed an adjusted earnings per share (EPS) of -$2.87, falling short of the anticipated -$2.58 EPS.
Vicarious Surgical confirmed its commitment to the previously stated full-year 2024 cash burn guidance of approximately $50 million. The company also indicated that it is on schedule with the integration of its V1.0 system, expected to occur within the next few weeks. This development is a significant step towards the company's goal to treat its first patient within the next 12 months, marking its first-in-human procedure.
Furthermore, Vicarious Surgical is in the process of selecting specific sites for an overseas clinical trial for ventral hernia. This step is part of the company's strategy to advance its clinical programs and prepare for commercialization.
Despite the lowered price target, the firm acknowledged the long-term potential of Vicarious Surgical's differentiated technology. The statement from Piper Sandler emphasized a cautiously optimistic outlook, expressing enthusiasm for the company's innovative approach while awaiting further progress and clearer visibility towards commercial success.
The analyst's comments reflect a watchful stance on Vicarious Surgical, balancing the recognition of the company's technological innovation with the practical considerations of its path to commercial viability and market penetration.
In other recent news, Vicarious Surgical Inc. reported a narrowed net loss in its Third Quarter 2024 Earnings Call, indicating a significant progress in their financial health. The company's adjusted net loss for the quarter was down to $17 million from last year's $20.4 million, accompanied by a 17% decrease in operating expenses, which totaled $17.8 million. Vicarious Surgical also maintains a strong cash position with $61 million in hand, projecting a cash burn of $50 million for the year.
In terms of technological advancements, the company is nearing the completion of its single-port robotic surgery platform. CEO Adam Sachs revealed that they expect to treat the first patient within a year, initiating with ventral hernia repairs in clinical trials outside the U.S. These trials are planned to enroll between 30 to 60 subjects to validate the system's safety and efficacy.
Despite the net loss, the company's financial stability is evident in its projected cash runway into 2026. The company's focus now shifts to the successful completion of clinical trials and the subsequent introduction of their technology to the market. These are the recent developments in Vicarious Surgical's journey.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Vicarious Surgical Inc.'s financial position and market performance. The company's market capitalization stands at $52.84 million, reflecting its current valuation in the market.
InvestingPro Tips highlight that Vicarious Surgical holds more cash than debt on its balance sheet, which could provide some financial flexibility as the company works towards its clinical and commercial goals. However, it's also noted that the company is quickly burning through cash, aligning with the analyst's focus on the full-year 2024 cash burn guidance of approximately $50 million.
The stock has shown significant momentum recently, with a strong return of 73.79% over the last month and an impressive 113.82% over the last three months. This performance might be attributed to investor optimism surrounding the company's progress with the V1.0 system integration and upcoming first-in-human procedure.
It's worth noting that InvestingPro offers 12 additional tips for Vicarious Surgical, providing a more comprehensive analysis for investors interested in delving deeper into the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.